Genzyme (also known as Genzyme Transgenics Corp or GTC Biotherapeutics) was an American biotechnology company based in Cambridge, Massachusetts. From its acquisition in 2011 to 2022 Genzyme operated as a fully owned subsidiary of Sanofi. In 2010, Genzyme was the world's third-largest biotechnology company, employing more than 11,000 people ...

Feb 3, 2022 · Eleven years after Sanofi bought Genzyme for about $20.1 billion, the parent company said Thursday it will no longer call its specialty care unit Sanofi Genzyme ― just Sanofi, as part of a ...

Jan 21, 2025 · French drugmaker Sanofi received a warning letter from the US Food and Drug Administration (FDA) last week for failing to comply with its current good manufacturing (cGMP) requirements for active pharmaceutical ingredients (API). The agency said the company needs to empower its quality unit to take steps to stay in regulatory compliance.

Genzyme Corporation is a leading biotechnology company that focuses on five business areas: therapeutics, diagnostic services, diagnostic products, pharmaceutical and fine chemicals, and tissue repair.

Feb 26, 2024 · A manufacturing problem from 15 years ago and the resulting prolonged drug shortage is at the heart of newly revived litigation against Sanofi’s Genzyme. An appeals court overturned the dismissal of a 2020 lawsuit brought by patients who allege they were harmed by Genzyme’s handling of a shortage of its drug Fabrazyme.

Jan 21, 2025 · Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a U.S. drug ingredients plant tied to its longstanding subsidiary...

Jan 22, 2025 · The FDA has issued a warning letter to Sanofi’s Genzyme facility in Framingham, Massachusetts, citing multiple manufacturing violations. Despite the regulatory scrutiny, Sanofi confirmed that there has been no disruption to the supply of drugs from the plant.

Sanofi Genzyme (also known as Genzyme Corporation) is a biotech company that specializes in rare diseases, rare blood disorders, multiple sclerosis, oncology, and immunology. It is engaged in the development of specialty care therapies to target a range of serious medical conditions.

French drugmaker Sanofi-Aventis SA clinched its long-sought deal for Genzyme Corp with a sweetened $20.1 billion cash offer, plus payments tied to the success of the U.S. biotech group's drugs.

Aug 1, 2014 · Genzyme Corporation manufactures, markets and/or distributes more than 10 drugs in the U.S.